Partners | iQone Healthcare Switzerland

EXISTING PARTNERS

iQone Healthcare Switzerland’s major partner Celltrion Healthcare is a global pharmaceutical company which is committed to delivering more affordable advanced therapeutics for patients. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion, Inc. through an extensive global network. Celltrion Healthcare’s products are manufactured at state-of-art mammalian cell culture facilities with 190,000 liters capacity, designed and built to comply with US FDA’s cGMP and the EMA’s GMP standards. Together with Celltrion Healthcare, iQone Healthcare Switzerland brings the advanced therapeutic solutions to patients and caregivers.

COMPANY BROCHURE CELLTRION

In April 2018 iQone Healthcare Switzerland started a co-promotion partnership with Mepha, Switzerland’s best-known generic supplier, for the product Remsima. Under the terms of the partnership, Mepha supports iQone Healthcare Switzerland with the distribution of the product and helps increase the level of service to physicians and pharmacists

BECOME PARTNER

iQone Healthcare Switzerland has a longstanding experience in pharmaceutical products and is pioneering biologics and biosimilars. We are a secure, trustworthy partner with activities covering every aspects of new drugs market entry and commercialization including medical expertise in Switzerland. Therefore, iQone Healthcare Switzerland is a partner of choice for international biopharmaceutical specialty companies seeking to penetrate efficiently the Swiss market.

CONTACT POINT FOR PARTNERS

WHY WE ARE DIFFERENT

iQone Healthcare Switzerland is committed to supporting partners with high responsiveness to demands, leading to important time savings and reducing uncertainty. This engagement is powered by our deep understanding of physicians’ needs to bring them unique therapeutic solutions based on new paradigms and innovation.

INTERNATIONAL PRESENCE

iQone Healthcare Switzerland is headquartered in Versoix, Switzerland, but is active in many European markets with Clinigen Europe, in partnership with specialty pharmaceutical companies. In the Swiss market, Mepha is our partner for the distribution of biologics and biosimilars.

PIPELINE

Our partner Celltrion Healthcare is developing several new biosimilars and biologics.

MONOCLONAL – ANTIBODY BIOSIMILARS:

Project	INN1	Mechanism of action	Major indications
Remsima SC / CT-P13	Infliximab	TNF-α inhibition	Rheumatoid arthritis, IBD
CT-P05	Etanercept	TNF-α inhibition	Rheumatoid arthritis
CT-P14	Palivizumab	Prevention of RSV2	Respiratory diseases
CT-P15	Cetuximab	EGFR inhibition	Colorectal cancer
CT-P16	Bevacizumab	VEGF inhibition	Colorectal cancer, Breast Cancer, NSCLC
CT-P17	Adalimumab	VEGF inhibition	Rheumatoid arthritis, Psoriatic arthritis, IBD
CT-P39	Omalizumab	Immunoglobulin E inhibition	Asthma, Urticaria

Anticancer mAb biosimilar approved by FDA, EMA and MFDS:

Brand name	INN	Indication
Herzuma	Trastuzumab	HER 2 positive metastatic breast cancer, early cancer, and metastatic gastric cancer

ANTIBODY BIOLOGICS:

Project	Molecular type	Target Indication
CT-P27	Monoclonal antibody	Pandemic / seasonal influenza
CT-P26	Antibody-drug conjugate	Breast cancer
CT-P19	Monoclonal antibody	Rabies
CT-P24	Monoclonal antibody	Hepatitis B virus
CT-P25	Cell culture vaccine	Influenza
CT-P59	Vaccine	COVID-19

IMDs:

Project	Indication
CT-G20	Cardiomyopathy